Human Study Associates Alcotox™ Supplementation to Improved Liver Biomarkers and Reduced Hangover Incidence

A new human study confirms Alcotox™ reduces alcohol-related liver enzyme elevations and hangover symptoms, validating its patent-pending approach to acetaldehyde defence.

LONDON, UK, August 04, 2025 /24-7PressRelease/ — Alcotox Ltd today announced the publication of a human observational study showing that supplementation with Alcotox™ was associated with improved liver enzyme markers and a lower incidence of self-reported hangover symptoms during the study.

The study, now available on ResearchGate, involved 70 adult participants undergoing a supervised alcohol challenge. The supplement tested contained Alcotox Matrix™ — a proprietary, patent-pending formulation developed by Alcotox Ltd to support acetaldehyde clearance — now featured across the company’s broader product range.

Key Findings
Outcome – Control Group – Alcotox™ Group
ALT (Liver Enzyme) – Significant increase – Significant reduction (P < 0.003)
AST (Liver Enzyme) – Significant increase – Suppressed increase (P < 0.05)
Hangover Symptoms – 65.4% incidence – 13.6% incidence (P < 0.01)
Adverse Effects – None reported – None reported

Mechanism: Targeting Acetaldehyde at the Source
Acetaldehyde — a toxic metabolite of alcohol — is primarily processed by the liver and is known to play a key role in liver stress, inflammation and hangover symptoms. Unlike ethanol, which is rapidly cleared, acetaldehyde is chemically reactive and persistent. It binds irreversibly to proteins and DNA, generating free radicals and triggering inflammatory cascades. This molecular reactivity is also implicated in the broader biological effects of alcohol — including tissue damage, neurochemical pathways linked to alcohol addiction and increased cancer risk.

Alcotox Matrix™ is a scientifically engineered blend of antioxidants, amino acids, and micronutrients formulated to support the body’s natural defence against acetaldehyde — without relying on enzyme blockers, aversion therapy, or pharmacological suppression.

Dr Imad Naasani, Chief Scientific Officer:
“The data show that acetaldehyde is a valid target for mitigating alcohol-related biological stress — and Alcotox Matrix™ engages that pathway effectively in a supervised, real-world setting.”

Platform Validation
Alcotox Matrix™ now underpins Alcotox Ltd’s growing product ecosystem — including capsules, liquid shots, and functional beverages — providing a single biochemical foundation across multiple delivery formats.

Alcotox products are not intended to treat, cure or prevent any diseases.

Media & Investor Contact:
info@alcotox.com
www.alcotox.com

About Alcotox Ltd
Alcotox Ltd is a UK-based life sciences company focused on the role of acetaldehyde in alcohol-related biological stress. Its patent-pending Alcotox Matrix™ supports the body’s natural response to this burden and underpins a multi-format consumer wellness portfolio spanning capsules, liquid shots, and functional beverages. Alcotox sits at the intersection of wellness, functional drinks, and biotech innovation.


For the original version of this press release, please visit 24-7PressRelease.com here

Legal Disclaimer:

The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at retract@kyrionmedia.com with the specific URL of the content in question. We will review and address valid requests promptly.